Blueprint Medicines Corporation
BPMC
Rang in aandelen
#2365
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Aandeelprijs
$129.46
Laatst gesynchroniseerd: 2025-07-18
Marktkapitalisatie
$8.36B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Blueprint Medicines Corporation (BPMC)
Categorie
Healthcare
Aantal uitstaande aandelen voor Blueprint Medicines Corporation (BPMC)
Aantal uitstaande aandelen per March 2025: 63.60M
Volgens de laatste financiële rapporten en de aandelenkoers van Blueprint Medicines Corporation bedraagt het huidige aantal uitstaande aandelen 63.60M. Aan het einde van December 2023 had het bedrijf 60.56M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Blueprint Medicines Corporation (BPMC) van 2013 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 63.60M | 1.18% |
| 2024 | 62.86M | 3.80% |
| 2023 | 60.56M | 1.54% |
| 2022 | 59.64M | 1.92% |
| 2021 | 58.52M | 7.31% |
| 2020 | 54.53M | 14.02% |
| 2019 | 47.83M | 9.03% |
| 2018 | 43.87M | 16.07% |
| 2017 | 37.79M | 37.47% |
| 2016 | 27.49M | 50.76% |
| 2015 | 18.24M | 39.38% |
| 2014 | 13.08M | 0.00% |
| 2013 | 13.08M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 253.90M | 299.21% |
US
|
|
| 396.00M | 522.64% |
US
|
|
| 478.91M | 653.01% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -2.22% |
NL
|
